Shruthi Ravimohan1, Sara C Auld2, Pholo Maenetje3, Nelly Ratsela3, Mandla Mlotshwa3, Itai Ncube3, Jonathan P Smith2, Mboyo-Di-Tamba Vangu4, Modulakgotla Sebe3, Andrew Kossenkov5, Drew Weissman1, Robert S Wallis3, Gavin Churchyard3,6,7, Hardy Kornfeld8, Gregory P Bisson1,9. 1. Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine at the University of Pennsylvania, Philadelphia. 2. Emory University Rollins School of Public Health and School of Medicine, Atlanta, Georgia. 3. The Aurum Institute, Johannesburg. 4. Nuclear Medicine, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, South Africa. 5. The Wistar Institute, Philadelphia, Pennsylvania. 6. Advancing Care and Treatment for Tuberculosis/Human Immuondeficiency Virus, A Collaborating Centre of The South African Medical Research Council. 7. School of Public Health, University of the Witwatersrand, Johannesburg, South Africa. 8. Department of Medicine, University of Massachusetts Medical School, Worcester. 9. Department of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Abstract
BACKGROUND: Immune restoration on antiretroviral therapy (ART) can drive inflammation in people living with human immunodeficiency virus (HIV) who have pulmonary tuberculosis (TB), but its effects on the lungs have not been assessed. We evaluated associations between pulmonary inflammation, recovery of pathogen-specific CD4 T-cell function, and lung injury prior to and after ART initiation in adults with HIV and pulmonary TB. METHODS: This was a prospective cohort study in South Africa, following adults with HIV and pulmonary TB prior to and up to 48 weeks after ART initiation. Pulmonary-specific inflammation was defined as total glycolytic activity (TGA) on [18]F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) at baseline and 4 weeks after ART initiation. Spirometry, respiratory symptom tests, and flow cytometry were performed at the same times to assess lung involvement and the frequency of mycobacteria-specific CD4 T-cells. In addition, we evaluated lung function longitudinally up to 48 weeks after ART initiation. RESULTS: Greater lung TGA on FDG PET-CT was associated with worse lung function and respiratory symptoms prior to ART initiation, and nearly half of subjects experienced worsening lung inflammation and lung function at Week 4 of ART. Worsening Week 4 lung inflammation and pulmonary function were both associated with greater increases in pathogen-specific functional CD4 T-cell responses on ART, and early decreases in lung function were independently associated with persistently lower lung function months after TB treatment completion. CONCLUSIONS: Increases in pulmonary inflammation and decreases in lung function are common on ART, relate to greater ART-mediated CD4 T-cell restoration, and are associated with the persistent impairment of lung function in individuals with HIV/TB.
BACKGROUND: Immune restoration on antiretroviral therapy (ART) can drive inflammation in people living with human immunodeficiency virus (HIV) who have pulmonary tuberculosis (TB), but its effects on the lungs have not been assessed. We evaluated associations between pulmonary inflammation, recovery of pathogen-specific CD4 T-cell function, and lung injury prior to and after ART initiation in adults with HIV and pulmonary TB. METHODS: This was a prospective cohort study in South Africa, following adults with HIV and pulmonary TB prior to and up to 48 weeks after ART initiation. Pulmonary-specific inflammation was defined as total glycolytic activity (TGA) on [18]F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) at baseline and 4 weeks after ART initiation. Spirometry, respiratory symptom tests, and flow cytometry were performed at the same times to assess lung involvement and the frequency of mycobacteria-specific CD4 T-cells. In addition, we evaluated lung function longitudinally up to 48 weeks after ART initiation. RESULTS: Greater lung TGA on FDG PET-CT was associated with worse lung function and respiratory symptoms prior to ART initiation, and nearly half of subjects experienced worsening lung inflammation and lung function at Week 4 of ART. Worsening Week 4 lung inflammation and pulmonary function were both associated with greater increases in pathogen-specific functional CD4 T-cell responses on ART, and early decreases in lung function were independently associated with persistently lower lung function months after TB treatment completion. CONCLUSIONS: Increases in pulmonary inflammation and decreases in lung function are common on ART, relate to greater ART-mediated CD4 T-cell restoration, and are associated with the persistent impairment of lung function in individuals with HIV/TB.
Authors: Diane V Havlir; Michelle A Kendall; Prudence Ive; Johnstone Kumwenda; Susan Swindells; Sarojini S Qasba; Anne F Luetkemeyer; Evelyn Hogg; James F Rooney; Xingye Wu; Mina C Hosseinipour; Umesh Lalloo; Valdilea G Veloso; Fatuma F Some; N Kumarasamy; Nesri Padayatchi; Breno R Santos; Stewart Reid; James Hakim; Lerato Mohapi; Peter Mugyenyi; Jorge Sanchez; Javier R Lama; Jean W Pape; Alejandro Sanchez; Aida Asmelash; Evans Moko; Fred Sawe; Janet Andersen; Ian Sanne Journal: N Engl J Med Date: 2011-10-20 Impact factor: 91.245
Authors: Grant Theron; Jonny Peter; Richard van Zyl-Smit; Hridesh Mishra; Elizabeth Streicher; Samuel Murray; Rodney Dawson; Andrew Whitelaw; Michael Hoelscher; Surendra Sharma; Madhukar Pai; Robin Warren; Keertan Dheda Journal: Am J Respir Crit Care Med Date: 2011-04-14 Impact factor: 21.405
Authors: Olalekan A Uthman; Charles Okwundu; Kayode Gbenga; Jimmy Volmink; David Dowdy; Alimuddin Zumla; Jean B Nachega Journal: Ann Intern Med Date: 2015-07-07 Impact factor: 25.391
Authors: Anne Bourgarit; Guislaine Carcelain; Valerie Martinez; Caroline Lascoux; Veronique Delcey; Brigitte Gicquel; Eric Vicaut; Philippe H Lagrange; Daniel Sereni; Brigitte Autran Journal: AIDS Date: 2006-01-09 Impact factor: 4.177
Authors: Frank Heuts; Dolores Gavier-Widén; Berit Carow; Julius Juarez; Hans Wigzell; Martin E Rottenberg Journal: Proc Natl Acad Sci U S A Date: 2013-04-04 Impact factor: 11.205
Authors: Samantha S C Kon; Jane L Canavan; Sarah E Jones; Claire M Nolan; Amy L Clark; Mandy J Dickson; Brigitte M Haselden; Michael I Polkey; William D-C Man Journal: Lancet Respir Med Date: 2014-02-04 Impact factor: 30.700
Authors: Graeme Meintjes; Cari Stek; Lisette Blumenthal; Friedrich Thienemann; Charlotte Schutz; Jozefien Buyze; Raffaella Ravinetto; Harry van Loen; Amy Nair; Amanda Jackson; Robert Colebunders; Gary Maartens; Robert J Wilkinson; Lutgarde Lynen Journal: N Engl J Med Date: 2018-11-15 Impact factor: 91.245
Authors: Jamilah Meghji; Maia Lesosky; Elizabeth Joekes; Peter Banda; Jamie Rylance; Stephen Gordon; Joseph Jacob; Harmien Zonderland; Peter MacPherson; Elizabeth L Corbett; Kevin Mortimer; Stephen Bertel Squire Journal: Thorax Date: 2020-02-26 Impact factor: 9.139
Authors: Andrew R DiNardo; Tanmay Gandhi; Jan Heyckendorf; Sandra L Grimm; Kimal Rajapakshe; Tomoki Nishiguchi; Maja Reimann; H Lester Kirchner; Jaqueline Kahari; Qiniso Dlamini; Christoph Lange; Torsten Goldmann; Sebastian Marwitz; Jeffrey D Cirillo; Stefan H E Kaufmann; Mihai G Netea; Reinout van Crevel; Anna M Mandalakas; Cristian Coarfa Journal: Eur Respir J Date: 2022-09-15 Impact factor: 33.795
Authors: Sara C Auld; Hardy Kornfeld; Pholo Maenetje; Mandla Mlotshwa; William Chase; Mboyo di-Tamba Vangu; Drew A Torigian; Robert S Wallis; Gavin Churchyard; Gregory P Bisson Journal: BMC Pulm Med Date: 2021-01-07 Impact factor: 3.320